Reproductive Health Science Ltd Michelle Fraser, Chief Executive Officer

25 August 2016

“IMPROVING HEALTH AND RESEARCH OUTCOMES THROUGH THE APPLICATION OF OUR FRONTIER TECHNOLOGIES WITH A LEAD FOCUS

BEING PREIMPLANTATION SCREENING TO IMPROVE IVF SUCCESS”

For

per

sona

l use

onl

y

2

Any forward looking statements in this presentation have been prepared on the basis of anumber of assumptions which may prove incorrect and the current intentions, plans, expectationsand beliefs about future events are subject to risk, uncertainties and other factors, many ofwhich are outside Reproductive Health Science Limited’s control.

Important factors that could cause actual results to differ materially from any assumptions orexpectations expressed or implied in this presentation include known and unknown risks. Asactual results may differ materially to any assumptions made in this presentation, you areurged to view any forward looking statements in this presentation with caution.

This presentation should not be relied on as a recommendation or forecast by ReproductiveHealth Science Limited, and should not be construed as either an offer to sell or a solicitation ofan offer to buy or sell shares in any jurisdiction.

For

per

sona

l use

onl

y

3

RHS has maintained a focus on being “At the forefront of single cell analysis”

RHS has a state-of-the-art advanced single cell Whole Genome Amplification (WGA) product DOPlifyTM that enables analysis by NGS (Next Generation Sequencing) &/or microarray pathways

RHS has been built on our particular interest in IVF outcomes, with a robust array for Pre-implantation Genetic Screening (PGS) known as EmbryoCellectTM and capabilities for NGS extending through to combined PGS & Pre-implantation Genetic Diagnosis (PGD)F

or p

erso

nal u

se o

nly

4

DOPlifyTM is a whole genome amplification kit that; Captures RHS proprietary know-how for the lysis and

Whole Genome Amplification (WGA) of single or small numbers of cells providing a solution for the amplification of limited DNA for a range of downstream applications

Addresses the first critical step in analysis accuracy – the quality of amplification before interpretation by array or NGS

EmbryoCellectTM microarray PGS kit is designed to meet the needs of the IVF industry; this kit uses DOPlifyTM as the first step for the microarray analysisF

or p

erso

nal u

se o

nly

5

DOPlifyTM is a solution to analysis of “micro” quantities of DNA such as a single cell which need to be multiplied before analysis

The DNA multiplying step is Whole Genome Amplification (WGA)

Accuracy of the subsequent DNA analysis is directly linked to the quality of the preceding WGA multiplication step

Analysis/interrogation of the products of the amplification step can be by a range of approaches including NGS or array technologies

The most advanced routine application is in the IVF industry with embryo biopsies of a single or small number of cells

For

per

sona

l use

onl

y

6

cellDNA

1,000,000s of picograms of DNA from 1 cellCopies of the whole genome

chromosomes

6 picograms of DNA

Lysis

WGA

For

per

sona

l use

onl

y

7

DNA is made up of 4 bases, adenine (A), guanine (G), cytosine (C) and thymine (T)

These bases make up the genetic code, determining the biology of a cell

Sequencing is determining the genetic code of DNA. Once the code is determined, the fragment of DNA is matched and compared to a reference sequence

By Zephyris at the English language Wikipedia, CC BY-SA 3.0, https://commons.wikimedia.org/w/index.php?curid=6285050

This can provide information on identity, genetic mutations and diseases for example

Next Generation Sequencing (NGS), also known as massively parallel sequencing, is a method to sequencing millions of fragments of DNA at the same time. This increases throughput and brings down the cost

For

per

sona

l use

onl

y

8

DOPlifyTM

www.abmgood.com

Bioinformatics1. Checking the quality of the sequencing run2. Working out where the >1million DNA fragments match

within the entire human genome3. Looking for differences with the reference genome4. Determining whether the differences are clinically

significant or not using published databases

Sequencing1. Library preparation

2. Determining the DNA code

http://www.broadinstitute.org/gatk/

For

per

sona

l use

onl

y

9

1 10 100 1,000 10,000 100,000

Low template NGS

Standard NGS

Microarray

5 cells

Single cell

Cell equivalents of DNA input required (log scale)

For

per

sona

l use

onl

y

10

RHS products compete across the DNA amplification, microarray and sequencing markets

RHS product CompanyDOPlifyTM Rubicon Genomics Inc, Sigma-Aldrich Co

LLC, Qiagen NV, Yikon Genomics

EmbryoCellectTM Illumina Inc, Agilent Technologies Inc, Natera Inc, Oxford Gene Technologies

Next Generation Sequencing workflows

Illumina Inc, Fluidigm Corp, Thermo Fisher Scientific

For

per

sona

l use

onl

y

11

RHS is one of only four companies in the world with an advanced single cell Whole Genome Amplification product Competing products PicoPLEX (Rubicon Genomics, which is equivalent

to SurePlex from Illumina) and GenomePlex (Sigma) use linker adapter Polymerase Chain Reaction (PCR), REPLI-g (Qiagen) uses Multiple Displacement Amplification (MDA) and Yikon Genomics sell a kit using MALBAC.

DOPlifyTM is unique in that it is based on advanced DOP-PCR, a modern version of a proven WGA approach

Polymerase Chain Reaction (PCR) is a molecular biology technique to copy DNA in much the same way as a cell usually copies its DNA during cell division

For

per

sona

l use

onl

y

12

Uses the high processivity and fidelity of new generation polymerases that are NGS application grade

Uses “ready-mixes” to minimise the pipetting steps and requires only 2 sample tube openings to reduce the risk of contamination

Provides an amplification system that is flexible enough to concurrently whole genome amplify a sample whilst specifically amplifying genes of clinical interest, reducing the risk of allele drop-out and;

The kit is highly stable during shipping and storageFor

per

sona

l use

onl

y

13

The single cell analysis market is forecast at US$5B by 2024 (http://www.grandviewresearch.com/industry-analysis/single-cell-analysis-market, July 2016)

Growth predicted to mainly come from consumables, which is currently the largest segment

Instruments will also grow but their high cost and long shelf-life will be limiting

While RHS Ltd was founded from interest in reproductive outcomes, the significant advantages that DOPlify™ provides over other WGA products is a platform for RHS to expand from our original target market

DOPlifyTM is a platform technology with global applicability There is no further product development required to use the

product in a range of different non-IVF applications

For

per

sona

l use

onl

y

Schilling, D. et al. (2012) Isolated, disseminated and circulating tumour cells in prostate cancer Nat. Rev. Urol. doi:10.1038/nrurol.2012.136

Permission obtained from Thieme © Schilling, D. et al. Mechanisms of tumour cell dissemination and methods for detection of circulating tumour cells in transitional cell carcinoma. Aktuelle Urol. 42, 122–127 (2011).

Diversity within a tumour• Growth characteristics• Prediction of treatment response• Metastatic potential

Detection and characterisation of circulating tumour cells• Identification and prognosis of primary source• Mutation rate compared to tumour• Prediction and monitoring of treatment

response• Treatment effectiveness and recurrence

14F

or p

erso

nal u

se o

nly

15

179 labs conducting DNA analysis in 50 states in the USA Approx. 40,000 cases received per year, approx. 25,000 cases

analysed Commonly used STR markers require 250pg of starting DNA template Termed low copy number analysis if less than 100pg of DNA available

More technical artefacts, evidence not widely accepted in court

Approx. 300,000 paternity tests per year

By using the RHS combined Whole Genome Amplification and single gene enrichment protocol, it may be possible to obtain genetic fingerprints using STR markers from limited templateF

or p

erso

nal u

se o

nly

16

Identification of individuals can be achieved using mitochondrial DNA, which is maternally inherited

RHS internal benchmarking has shown that DOPlifyTM

provides greater coverage of the mitochondrial genome than competing WGA kit PicoPLEX

Mitochondrial DNA sequence analysis of single cells amplified using either DOPlifyTM or PicoPLEX (Rubicon). Libraries were prepared using standard Nextera protocol and sequenced in a 23-plex paired-end 150-bp read format on the Illumina NextSeq

For

per

sona

l use

onl

y

17

Using Whole Genome Amplification, all of the DNA in a sample will be amplified, providing a more abundant template for analysis.

http://earthsciences.typepad.com/blog/2011/07/harnessing-metagenomics-to-study-microbial-ecology-in-soils.html

Environmental DNA and conservation Human microbiome

The microbiome of individuals may differ due to such factors as diet, environmental influences and genetics. The effects of therapeutic treatments, stress and the ability to restore the microbiome rely on the accurate characterisation of its contents

https://www.neb.com/tools-and-resources/feature-articles/addressing-challenges-in-microbiome-dna-analysis

For

per

sona

l use

onl

y

18

China, 250,000

USA, 163,000Russia, 80,000

Iran, 35,000

UAE and Saudi Arabia, 8,000

Turkey, 45,000

India, 80,000

Indonesia, 3,500Israel, 32,000

South Africa, 5,500Australia, 62,000

1.7 million IVF cycles per annum globally, growing at 10%Estimated 5 million IVF babies born, an average of one per classroomAverage of 4 embryos per cycle

For

per

sona

l use

onl

y

0%

10%

20%

30%

40%

50%

60%

70%

80%

90%

<35 35-37 38-40 41-42 >42

Embr

yo A

neup

loid

y In

cide

nce

Maternal age

Even younger IVF patients have significant numbers of aneuploid embryos

Harton et al 2013

19

0102030405060708090

100

Euploid embryos Aneuploid embryos

Num

ber o

f tr

ansf

ers

Live birth or ongoingpregnancy

Unsuccessful

96% of the aneuploid embryos (i.e. embryos with the incorrect number of chromosomes) failed to implant resulting in an unsuccessful IVF transfer Scott et al 2012F

or p

erso

nal u

se o

nly

20

Decrease time to pregnancy Positive clinical outcome

Trend towards increased maternal age

Decreased miscarriages

Increased single embryo transfers reducing clinical complications from multiple pregnancies eg preterm birth

Patient and Medicare savings Clinic decreases revenues from storage and subsequent

transfer of aneuploid embryos Additional revenues from PGS

Patient expectations of best practice and clinical duty of careFor

per

sona

l use

onl

y

21

The RHS PGS service was established to provide support to clinics introducing PGS

“Rollout” is by direct PGS service provision and also supported sales flindersfertility is a functioning model of clinicians and scientists

working together to determine the patient needs, providing the option of fresh embryo transfer and identification of euploid embryos prior to freezing

Morula IVF are an example of RHS assisting in the establishment of in-house capability, which is now self-sufficient

Revenue from a PGS service business offered to 10,000 cycles in Australia, assuming 30% PGS uptake, approximates the RHS total cash burn rate

Broader roll out of this service model is anticipated both nationally and internationally

For

per

sona

l use

onl

y

22

The US PGS market is primarily a sophisticated service offered to clinics

2014 data indicated that less than 6% of IVF cycles in the US use PGS, but this has grown to 20% in 2016

By 2020, RHS aims to be addressing 20% of the global PGS market, which is forecast to represent 20% of the global IVF market of approximately 2 million cycles

For

per

sona

l use

onl

y

23

The RHS DOPlifyTM WGA platform offers clinicians and their patients choice and flexibility for analysis of the precious embryo biopsy. EmbryoCellectTM for cost efficient PGS, particularly under the time

constraint for fresh transfer and to determine which embryos are suitable for frozen storage

NGS after DOPlifyTM is ideally suited for PGD needs including translocations and specific inherited genetic disorders. It is possible to pre-determine clinically relevant regions to analyse; hence RHS developed a unique and improved combined PGS-PGD approach

For

per

sona

l use

onl

y

24

Marketing DOPlifyTM in parallel with EmbryoCellect™ to provide flexibility to select the best technology for clinical needs. Clinicians can determine on a patient-by-patient basis the extent of

genetic information needed and tailor their screening accordingly.

Additionally, RHS has been able to demonstrate that by using DOPlifyTM it is possible to screen an embryo for changes in chromosome number (PGS) and at the same time detect the presence of a genetic disease (PGD) carried by patients that needs to be avoided during embryo transfer, such as Duchenne’s Muscular Dystrophy.

For

per

sona

l use

onl

y

25

The correct aneuploidy result is maintained and the targeted gene is evident using traditional PGD and also NGS approaches.

WGA + primers WGA only NTC

Test

Test

Control

Control

NGS data

0.000.250.500.751.001.251.501.752.00

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 X YN

egat

ive

Mea

n of

nor

mal

ized

ratio

s

Chromosome

0.00

0.50

1.00

1.50

2.00

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 X Y

Ratio of mapped reads compared to internal reference (~700,000 reads/sample)

1: 48,XXY,+21 D4S43 & Y enriched 2: 48,XXY,+21 D4S43 enriched 6: 48,XXY,+21 control

EmbryoCellectTM

For

per

sona

l use

onl

y

26

Released EmbryoCellectTM validation data showing the accuracy and sensitivity is competitive with other PGS products

Patent application for combined PGS & PGD filed Launched DOPlifyTM specifically targeting the NGS market

Demonstrated a major, globally-unrivalled technical advance in being able to concurrently whole genome amplify and specifically amplify genes of clinical significance from single cells

For

per

sona

l use

onl

y

27

With the recent expiry of IP rights that had prevented the Company from entering the USA market, RHS is now actively marketing EmbryoCellectTM

and DOPlifyTM in this market. The USA marketing strategy will be enhanced by recruitment of a senior executive and through RHS exhibiting at the American Society for Reproductive Medicine (ASRM) meeting in Salt Lake City in October 2016.

Consolidate and expand the NGS capabilities of the Company including incorporation into the PGS service business and model

The launch of DOPlifyTM is enhancing RHS’ position as a global leader in single cell genomic technologies. A number of significant opportunities are in progress due to our ability to respond to the advancing genetics market and to expand our focus to other important applications for single cell analysis. Commercial collaborations may lead to integration of DOPlifyTM into the workflows of products of large multinationals.

Cash flow positive by end 2017For

per

sona

l use

onl

y

Key assetsIntellectual property

EmbryoCellectTM microarray granted patent familyDOPlifyTM trade secret and supplier exclusivityDOPlifyTM combined single gene enrichment Provisional Patent pending

Primary value drivers

Clinical impact in the IVF marketSignificant technical advances and deep expertise in single cell genetic analysisGlobal product sales and key partnerships

24 August 2016 dataASX Code RHS

Shares on Issue 59m

Share Price 9.2c

Options 13.1m

Market Capitalisation $5.43m

Cash at 30 June 2016 $0.6m

Recent Corporate Highlights• DOPlifyTM launched August 2016• R&D Tax refund of $278k received• EmbryoCellectTM performance validation

data released

28F

or p

erso

nal u

se o

nly

29

Dr David BrookesNon-Executive Chairman

Director of Atcor Medical Holdings Ltd (ACG:ASX); medical practitioner & biotechnology consultant; MBBS; FACRRM; FAICD

Dr Michelle FraserManaging Director and CEO

PhD (molecular biology); Grad Dip Science & Technology Commercialisation; GAICD, RHS CEO since 2007

Ms Sue MacLemanNon-Executive Director

CEO of MTPConnect; has been CEO and a Board member of a number of publicly-listed companies in both the USA and Australia; BPharm; MMktg; MLaw; FACPP; FAICD

Mr Johnathon MatthewsNon-Executive Director

Executive Director of The Pipette Company; previously held positions at Australian Treasury, ASX and Commonwealth Bank; BEc; BComm; LLB; GAICD

Emeritus Professor Colin Matthews AO

Alternate Non-Executive Director

Inaugural director of RHS, Single Cell Pty Ltd, Flinders Fertility; co-founder and former director of The Pipette Company; former Director ReproMed; Chairman RHS’ Clinical & Scientific Advisory Committee

Mr Raymond RidgeCFO and Company Secretary

CFO and Co Sec Thor Mining, CFO Southern Gold; BA (Acc); CA; GIA (Cert)

Dr Melinda JasperCSO

PhD; Experience in reproductive molecular biology, pre-implantation genetic analysis and single cell PCR, RHS CSO since 2012

For

per

sona

l use

onl

y

Reproductive Health Science Ltd ASX:RHS Dr Michelle Fraser, CEO and MD

michelle.fraser@rhsc.com.au www.rhsc.com.au

For

per

sona

l use

onl

y